Cranberry A-type proanthocyanidins selectively target acute myeloid leukemia cells by Bystrom, L.M et al.
STIMULUS REPORT
Cranberry A-type proanthocyanidins selectively target acute myeloid
leukemia cells
Laura M. Bystrom,1 Daniel P. Bezerra,1 Hsiao-Ting Hsu,1 Hongliang Zong,1 Luis A. Lara-Martı´nez,1 Jeanne P. De Leon,1 Megan Emmanuel,1
David Me´ry,1 Sara Gardenghi,1 Duane Hassane,1 Catherine C. Neto,2 Susanna Cunningham-Rundles,3 Michael W. Becker,4
Stefano Rivella,5 and Monica L. Guzman1
1Department of Medicine, Weill Cornell Medical College, New York, NY; 2Department of Chemistry and Biochemistry, University of Massachusetts–Dartmouth, North
Dartmouth, MA; 3Department of Pediatrics, Weill Cornell Medical College, New York, NY; 4Department of Medicine, James P. Wilmot Cancer Center, Rochester, NY; and
5Department of Pediatrics, Children’s Hospital of Philadelphia, Philadelphia, PA
Key Points
• A-PACs target primary
AML cells, sparing
healthy CD341 cord
blood cells in vitro and
reducing AML tumor
burden with in vivo
treatment.
•NF-kB activation
plays a role in
A-PAC–induced
cell death.
Most elderly patients affectedwithacutemyeloid leukemia (AML)will relapse anddie of their
disease even after achieving complete remission, thus emphasizing the urgent need for new
therapeutic approaches with minimum toxicity to normal hematopoietic cells. Cranberry
(Vaccinium spp.) extracts have exhibited anticancer and chemopreventive properties that
have been mostly attributed to A-type proanthocyanidin (A-PAC) compounds. A-PACs,
isolated from a commercially available cranberry extract, were evaluated for their effects
on leukemia cell lines, primary AML samples, and normal CD341 cord blood specimens. Our
results indicated potent and speciﬁc antileukemia activity in vitro. In addition, the
antileukemia activity of A-PACs extended tomalignant progenitor and stem cell populations,
sparing their normal counterparts. The antileukemia effects of A-PACs were also
observed in vivo using patient derived xenografts. Surprisingly, we found that the
mechanism of cell death was driven by activation of NF-kB. Overall, our data suggest that
A-PACs could be used to improve treatments for AML by targeting leukemia stem cells
through a potentially novel pathway.
Introduction
Cranberry (Vaccinium spp.) A-type proanthocyanidins (A-PACs) are a unique class of compounds with
antitumor activity.1-7 A-PACs have epicatechin compounds (Figure 1A) linked by carbon2carbon bonds
and distinctive ether bonds associated with potent biological effects (Figure 1B-C).1,6
Acute myelogenous leukemia (AML) is an often fatal cancer with a high relapse rate8,9 attributed to a
chemoresistant population of leukemia stem cells (LSCs). Current therapies, including cytarabine
(Ara-C), eradicate the AML blast population, but are relatively ineffective against self-renewing and disease-
perpetuating LSCs.10-12 Patients with more LSCs demonstrate significantly shorter relapse-free survival
than patients with fewer LSCs.13 A higher proportion of LSCs at diagnosis is highly predictive of minimal
residual disease, suggesting a causal relationship.13 Several characteristics of LSCs could be exploited
as therapeutic targets: aberrant surface phenotype, dysregulated cell-survival programs, differentiation,
and microenvironmental interactions.14 In this study, we evaluated the ability of A-PACs to target AML
in vitro and in vivo, including blast and progenitor/stem cells, and investigated potential mechanisms.
Methods
Viability of primary AML/cord blood (CB) CD341 cells and leukemia/lymphoma cell lines were
assessed by flow cytometry using cell viability stains15 after 48 hours of treatment with CystiCran-40
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(NATUREX-DBS LLC; Sagamore, MA) extract (CYS) or A-PACs
isolated from CYS (A-PAC), as similarly described.6 Colony-forming
assays and patient-derived xenotransplants (PDX), using nonobese
diabetic/severe combined immunodeficient mice (Jackson Labora-
tories; Bar Harbor, ME), were conducted.15 Mouse bone marrow
cells were assessed by flow cytometry15 to evaluate if pretreatment
with A-PACs prevented AML engraftment or if treating established
xenograft mice intraperitoneally with A-PACs (25 m/kg 2 times
a week for 3 weeks) or Ara-C (60 mg/kg for 5 days) reduced AML
engraftment after 6 to 8 weeks (Figure 1I; supplemental Figure 1).
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Figure 1. A-PACs induce cell death in leukemia cell lines and primary AML cells while sparing healthy CD341 CB cells. (A) Epicatechin. (B) A-PAC dimer. (C)
A-PAC trimer. (D-E) Dose-response effects of cell lines and primary AML cells treated with CYS. (F-G) Dose-response effects of A-PACs on cell lines (group A, between blue
lines: high sensitivity; group B, between red lines: intermediate sensitivity; group C, between black lines: low sensitivity) and primary AML cells. (H) Normal cord blood CD341
cells treated with A-PACs. (I) Scheme for experimental design. (J) Colony-forming unit (CFU) for normal CD341 CB and AML samples treated with A-PACs; erythroid (Ery),
myeloid, and AML CFU percent relative to untreated. (K) Percent engraftment of primary AML cells untreated or treated with 62.5mg/mL A-PACs after 8 weeks. (L) Percent
engraftment of normal CD341 cells treated with and without 62.5 mg/mL A-PACs after 8 weeks. Data with mean 6 standard error of the mean (SEM) were significant if
*P , .05, **P , .01, ***P , .001 (Student t test). DMSO, dimethyl sulfoxide.
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Figure 2. Decrease in tumor burden with A-PAC in vivo treatment and the role of NF-kB in A-PAC–induced cell death. (A) Percent engraftment of AML 9 at
6 weeks posttransplant and 3 weeks after intraperitoneal treatments (A-PACs or phosphate-buffered saline 2 times/week for 3 weeks or with 60 mg/kg Ara-C daily for 5 days).
Percent leukemia burden is shown for the indicated treatments. Data represented as mean 6 SEM and significant if *P , .05; *P 5 .0332 (1-way analysis of variance).
(B) Pan-caspase inhibitor Z-VAD (20 mM) cannot rescue AML cells from A-PAC (250 mg/mL) cell death. (C) NF-kB gene family upregulation and cell death after 4 hours with
A-PACs (62.5 mg/mL; 31.25 mg/mL for Ramos). Cell lines from left to right: MV4-11 (green), K562 (red), REH (brown), MOLM-13 (purple), SKNO-1 (blue), Ramos (gray).
(D) NF-kB activation after 4 hours of A-PAC treatment in MOLM-13; positive control is 2.5 mg Jurkat (TPA1CI) nuclear extract. (E) A-PAC cell death after pretreatment with
NF-kB inhibitor SN50 (100 mg/mL) in 2 cell lines and a primary AML sample (blue arrows indicate line for LD50); shown with log concentration (mg/mL). (F) SN50 increased
the ability of parthenolide (PTL) to induce cell death in a primary AML10 cells; shown with log concentration (mM). (G) Activation of NF-kB after 4 hours of treatment with
A-PACs (32.25 mg/mL) or PTL (5 mM) with and without SN50 (36 mM) in AML10 cells. Data mean 6 SEM were significant if *P , .05, **P , .0 1, ***P , .001
(Student t test, with the exception of panel A). OD, optical density.
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Cells were pretreated with 100 mg/mL SN50 or 20 mM carbo-
benzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone
(Z-VAD; EMD Millipore) before A-PAC treatment in vitro. RNA was
prepared/assessed as previously described.16 The DNA-binding
capacity of NF-kB (p65 subunit) was measured from whole cell
extracts using the Nuclear Extract and TransAM NF-kB Kit (Active
Motif; Carlsbad, CA). For more experimental details, see supple-
mental Materials.
Results and discussion
We report concentration-dependent antileukemia activity of a cran-
berry extract (CYS, 40% A-PACs) and its purified A-PAC fraction
(A-PAC) against cell lines and primary AML samples (Figure 1D-G).
All cells were sensitive to A-PACs at 250 mg/mL (most .50%
cell death) (Figure 1F-G). At lower concentrations (62.5 and
31.25 mg/mL), differential sensitivity was observed in cell lines
(Figure 1F). At the higher A-PAC concentrations (125 and 250mg/mL),
normal CB CD341 cells showed ,30% cell death at 48 hours,
whereas cell death reached 94% in some primary AML samples
(Figure 1G-H). Therefore, A-PACs induced massive cell death in
leukemic cells, whereas healthy CD341CBcells weremostly spared.
Primary AML cells and CB cells treated in vitro below the median
lethal dose (LD50; 62.5 mg/mL), with a phenotypically defined
(CD341 CD382) stem cell population (supplemental Figure 2),
were evaluated for their ability to proliferate and differentiate into
colony-forming clones and for stem/progenitor cells to initiate
leukemia or engraft and reconstitute bone marrow in PDX models
(Figure 1I). We found .75% decrease in colony-forming activity of
AML stem/progenitor cells relative to vehicle control (Figure 1J).
Generation of erythroid/myeloid colonies in vitro was not signif-
icantly affected in normal CD341 CB cells treated with twice the
dose used for AML cells (Figure 1J). Furthermore, treatment of
primary AML cells resulted in significantly decreased engraft-
ment in nonobese diabetic/severe combined immunodeficient
mice, whereas treated normal CD341 cells retained engraft-
ment capacity (Figure 1K-L). These results indicate A-PACs have
potent activity against AML stem/progenitor cells without
harming normal hematopoietic counterparts.
The potent antitumor response of A-PACs in vitro led us to evaluate
A-PAC treatment in vivo. After PDX were established, mice were
randomized into groups with different treatments. We found
a greater than twofold decrease in AML tumor burden for mice
treated with A-PACs or Ara-C compared with vehicle-treated mice
(Figure 2A). This suggests A-PACs represent a novel class of
compounds that selectively kill AML cells in vivo.
The mechanism of cell death was evaluated by investigating
apoptosis and survival pathways. AML cells treated with A-PACs
required 6 to 8 hours to commit to cell death in wash-out
experiments (supplemental Figure 3). Because cleaved poly ADP
ribose polymerase, a marker of apoptosis, was apparent 8 hours
posttreatment in A-PAC–sensitive AML cells (supplemental Figure 4),
we evaluated if pan-caspase inhibitor Z-VAD could rescue 3
different AML cell lines from A-PAC–induced cell death. Z-VAD
was unable to rescue the cells, indicating A-PAC–induced cell
death is not caspase dependent (Figure 2B), consistent with
another report.17 Additionally, we found A-PAC increased AML
cell death when used in combination with the standard care drug
Ara-C (supplemental Figure 5).
We previously showed that NF-kB is constitutively activated in AML
cells (blast and stem/progenitor) and is important for cell survival,
whereas inhibition led to cell death with minimal damage to normal
hematopoietic cells.11 We evaluated the effect of A-PACs on
NF-kB by investigating transcriptional regulation of NF-kB family
genes 4 hours posttreatment. Figure 2C shows that leukemia cell
lines, with increasing A-PAC sensitivity, treated with 62.5 mg/mL
of A-PACs (31.25 mg/mL for highly sensitive Ramos cells), resulted
in increased expression of NF-kB family genes. Upregulation was
twofold higher in the most sensitive cells (Ramos), which also
exhibited inflammatory response gene expression (supplemental
Figure 6), and one- to 1.2-fold lower in the least sensitive cells
(MV4-11). Assessment of inflammatory cytokine induction by
A-PACs in sensitive AML cells indicated interleukin-8 levels
increased in the cell culture supernatant, suggesting a possible
relationship with NF-kB activation (supplemental Figure 7).
Using the RELA/p65 transcription factor DNA binding assay, we
also found significant activation of NF-kB 4 hours posttreatment
in MOLM-13 cells (Figure 2D). To determine if increased NF-kB
activity by A-PACs was relevant to cell death, we disrupted NF-kB
translocation to the nucleus using SN50 peptide.18 We observed
a shift in the LD50 after pretreating cells with SN50 (Ramos cells:
1.6-2.1 LD50 ratio; MOLM13: 1.9-2.4 LD50 ratio; AML10: 1.4-2.0
LD50 ratio) (Figure 2E). Therefore, NF-kB activation appears to be
necessary for A-PACs to induce cell death. Conversely, SN50
pretreatment increased AML cell death with the anti-LSC agent and
NF-kB inhibitor, parthenolide (PTL)10 (Figure 2F). To further confirm
SN50 inhibited A-PAC–induced activation of NF-kB, we used the
NF-kB p65 DNA binding assay with primary AML cells and found
SN50 blocked NF-kB activation by A-PACs, the opposite effect of
the anti-LSC agent PTL (Figure 2G). This suggests that other
means of perturbation of NF-kB, such as hyperactivation, can also
result in leukemia cell death.
AML is a disease that urgently needs novel and less toxic therapies
that also target LSCs. Currently, most approaches used to eliminate
LSCs involve inhibition of NF-kB, which is constitutively activated
in AML cells.10,11,19,20 Collectively, our previous and new data
suggest that perturbation (inhibition or hyperactivation) of
already altered pathways results in adverse responses to AML
cells. Moreover, we have demonstrated that A-PACs targeted
LSCs and blasts through a potentially novel pathway that
involves activation of NF-kB. To our knowledge, this is the
first report in which activation of NF-kB leads to primary AML
blast and progenitor/stem cell death without harming normal
counterparts.
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